JP2011520847A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520847A5 JP2011520847A5 JP2011508945A JP2011508945A JP2011520847A5 JP 2011520847 A5 JP2011520847 A5 JP 2011520847A5 JP 2011508945 A JP2011508945 A JP 2011508945A JP 2011508945 A JP2011508945 A JP 2011508945A JP 2011520847 A5 JP2011520847 A5 JP 2011520847A5
- Authority
- JP
- Japan
- Prior art keywords
- ethoxy
- xaa
- acetyl
- amino
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 *C(CCC(NCCOCC*CCOCCOCC(NCCCC[C@](C(P)=O)N*)O)O)[N+]([O-])=O Chemical compound *C(CCC(NCCOCC*CCOCCOCC(NCCCC[C@](C(P)=O)N*)O)O)[N+]([O-])=O 0.000 description 8
- XJXNZODHKPMSDQ-PLNGDYQASA-N C/C(/C(C)=O)=C/C(N)=C Chemical compound C/C(/C(C)=O)=C/C(N)=C XJXNZODHKPMSDQ-PLNGDYQASA-N 0.000 description 1
- CVMXXJSHVQQZRG-UHFFFAOYSA-N CC1CCC(CNC(CCCCCCCCCCCCCCCCCCC(O)[U])[U])CC1 Chemical compound CC1CCC(CNC(CCCCCCCCCCCCCCCCCCC(O)[U])[U])CC1 CVMXXJSHVQQZRG-UHFFFAOYSA-N 0.000 description 1
- JRMQQXSMFOBGII-UHFFFAOYSA-N O=CCCCCCCCCCCCCCCCCCNCC1CCCCC1 Chemical compound O=CCCCCCCCCCCCCCCCCCNCC1CCCCC1 JRMQQXSMFOBGII-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08156360 | 2008-05-16 | ||
| EP08156360.3 | 2008-05-16 | ||
| EP09154461 | 2009-03-05 | ||
| EP09154461.9 | 2009-03-05 | ||
| PCT/EP2009/055989 WO2009138511A1 (en) | 2008-05-16 | 2009-05-18 | Long-acting y2 and/or y4 receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011520847A JP2011520847A (ja) | 2011-07-21 |
| JP2011520847A5 true JP2011520847A5 (enExample) | 2012-07-05 |
Family
ID=40934036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011508945A Withdrawn JP2011520847A (ja) | 2008-05-16 | 2009-05-18 | 遅効型ｙ２及び／又はｙ４レセプターアゴニスト |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20110275559A1 (enExample) |
| EP (1) | EP2279204A1 (enExample) |
| JP (1) | JP2011520847A (enExample) |
| KR (1) | KR20110017874A (enExample) |
| CN (1) | CN102027007A (enExample) |
| AU (1) | AU2009248041B2 (enExample) |
| BR (1) | BRPI0912615A2 (enExample) |
| CA (1) | CA2723855A1 (enExample) |
| IL (1) | IL208836A0 (enExample) |
| MX (1) | MX2010011845A (enExample) |
| RU (1) | RU2504550C2 (enExample) |
| WO (1) | WO2009138511A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2450374B9 (en) | 2009-07-02 | 2016-11-23 | Takeda Pharmaceutical Company Limited | Peptide and use thereof |
| CN102573888A (zh) * | 2009-09-18 | 2012-07-11 | 诺和诺德公司 | 长效y2 受体激动剂 |
| EP2498800A1 (en) * | 2009-11-13 | 2012-09-19 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| GB201001333D0 (en) * | 2010-01-27 | 2010-03-17 | Imp Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| WO2012006566A2 (en) | 2010-07-09 | 2012-01-12 | Amylin Pharmaceuticals, Inc. | Microcrystalline y receptor agonists |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| RS58039B1 (sr) | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| EP2842965A1 (en) | 2013-09-03 | 2015-03-04 | Gubra ApS | Neuromedin U analogs comprising serum albumin binding amino acid residue |
| WO2015071355A1 (en) | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| ES2732015T3 (es) * | 2013-11-15 | 2019-11-20 | Novo Nordisk As | Compuestos de PYY selectivos y sus usos |
| WO2015073878A1 (en) * | 2013-11-15 | 2015-05-21 | Ur Diet, Llc | Real-time satiety biofeedback |
| US10583172B2 (en) | 2013-11-15 | 2020-03-10 | Novo Nordisk A/S | HPYY(1-36) having a beta-homoarginine substitution at position 35 |
| US20240100450A9 (en) * | 2014-01-17 | 2024-03-28 | Repligen Corporation | Sterilizing chromatography columns |
| EP3094391B1 (en) | 2014-01-17 | 2024-11-20 | Repligen Corporation | Sterilizing chromatography columns |
| CN114805527A (zh) * | 2014-05-21 | 2022-07-29 | 哈佛大学的校长及成员们 | Ras抑制肽和其用途 |
| MX392572B (es) * | 2015-06-12 | 2025-03-24 | Novo Nordisk As | Compuestos del péptido yy (pyy) selectivos y sus usos. |
| AR114353A1 (es) | 2018-02-02 | 2020-08-26 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
| TWI749381B (zh) * | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| GB201908426D0 (en) * | 2019-06-12 | 2019-07-24 | Imp College Innovations Ltd | Appetite suppressing compounds |
| CA3175725A1 (en) * | 2020-04-17 | 2021-10-21 | William Blackwell | Long acting peptide tyrosine tyrosine (pyy) analogs and methods of use |
| JP2024516395A (ja) | 2021-04-27 | 2024-04-15 | アードバーク・セラピューティクス・インコーポレイテッド | 苦味受容体アゴニストおよび腸シグナル伝達化合物の組み合わせ |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2123293A3 (en) * | 2000-12-14 | 2010-09-08 | Amylin Pharmaceuticals, Inc. | Peptide YY and petide YY agonists for treatment of metabolic disorders |
| EP1670515A2 (en) * | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| EP1789440A4 (en) * | 2004-02-11 | 2008-03-12 | Amylin Pharmaceuticals Inc | REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM |
| DK2060266T3 (da) * | 2004-03-17 | 2011-11-14 | 7Tm Pharma As | Y4-selektiv receptoragonist PP2-36 til terapeutiske indgreb |
| ES2542228T3 (es) * | 2004-07-08 | 2015-08-03 | Novo Nordisk A/S | Marcas de prolongación polipeptídica que comprenden un resto de tetrazol |
| CN101222942A (zh) * | 2005-07-18 | 2008-07-16 | 诺沃-诺迪斯克有限公司 | 用于治疗肥胖的肽 |
-
2009
- 2009-05-18 RU RU2010149474/04A patent/RU2504550C2/ru not_active IP Right Cessation
- 2009-05-18 JP JP2011508945A patent/JP2011520847A/ja not_active Withdrawn
- 2009-05-18 KR KR1020107027495A patent/KR20110017874A/ko not_active Withdrawn
- 2009-05-18 CN CN2009801173043A patent/CN102027007A/zh not_active Withdrawn
- 2009-05-18 AU AU2009248041A patent/AU2009248041B2/en not_active Ceased
- 2009-05-18 US US12/993,015 patent/US20110275559A1/en not_active Abandoned
- 2009-05-18 WO PCT/EP2009/055989 patent/WO2009138511A1/en not_active Ceased
- 2009-05-18 BR BRPI0912615A patent/BRPI0912615A2/pt not_active Application Discontinuation
- 2009-05-18 MX MX2010011845A patent/MX2010011845A/es not_active Application Discontinuation
- 2009-05-18 CA CA2723855A patent/CA2723855A1/en not_active Withdrawn
- 2009-05-18 EP EP09745843A patent/EP2279204A1/en not_active Withdrawn
-
2010
- 2010-10-20 IL IL208836A patent/IL208836A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2504550C2 (ru) | Длительно действующие агонисты рецепторов y2 и(или) y4 | |
| CN114901680B (zh) | 长效glp-1化合物 | |
| AU2014241743B2 (en) | Insulin-incretin conjugates | |
| JP2010538049A5 (enExample) | ||
| CN101868476B (zh) | 胰高血糖素样肽-1衍生物及其制药用途 | |
| CN114901683B (zh) | 胰岛素衍生物 | |
| JP6108659B2 (ja) | 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト | |
| US9657079B2 (en) | Truncated GLP-1 derivatives and their therapeutical use | |
| JP2016512213A5 (enExample) | ||
| JP2014521684A5 (enExample) | ||
| JP2014502252A5 (enExample) | ||
| CN108271356A (zh) | 肠降血糖素-胰岛素缀合物 | |
| JP2013545724A5 (enExample) | ||
| US9499600B2 (en) | Long-acting single-chain insulin analogues | |
| US20130096055A1 (en) | Long-acting y2 receptor agonists | |
| JP2008533105A5 (enExample) | ||
| CN107108716A (zh) | 双相性单链胰岛素类似物 | |
| CA2812951A1 (en) | Engineered polypeptides having enhanced duration of action | |
| JP2014500880A5 (enExample) | ||
| JP2012529463A5 (enExample) | ||
| JP2008507298A5 (enExample) | ||
| JP2010515686A5 (enExample) |